According to the Partnership for Safe Medicines...
...the U.S. Food and Drug Administration’s (FDA) annual Report on the State of Pharmaceutical Quality, active pharmaceutical ingredient (API) sites that solely supply compounding pharmacies are disproportionately high risk for regulatory action. These facilities only represent 18% of registered API manufacturers, but they drew 72% of the warning letters, import alerts, and regulatory meetings taken against API manufacturing sites over the last five years.
Read More
#Compounding
#SafetyAlerts